Lifeward Study Shows ReWalk Exoskeleton Improves Daily Activities, Satisfaction And Pain

Lifeward Ltd. (LFWD) published a study on long-term use of its ReWalk Personal Exoskeleton, showing positive results in seven individuals with chronic paraplegia. The study, conducted by Andrea Giovanni Cutti and colleagues, reported no falls or fractures, with participants walking a median distance of 129 meters in a six-minute test. The exoskeleton is FDA-cleared and CE Marked, covered by Medicare for eligible beneficiaries.

Lifeward Ltd. (LFWD) reported Q2 2026 revenue up 16% to $6.6 million from $5.7 million a year earlier. ReWalk sales rose 13% to $2.5 million and AlterG products and services rose 25% to $4.1 million. Gross margin fell to 41%. Operating loss narrowed to $4.2 million. Cash was $9.4 million at June 30, 2026.

Lifeward Ltd. (Nasdaq: LFWD) reported Q2 2026 revenue up 16% to $6.6 million from $5.7 million a year earlier, driven by ReWalk sales rising 13% to $2.5 million and AlterG products and services up 25% to $4.1 million. Gross margin was 41%. Net loss was $11.5 million ($4.12/share). The company said it raised about $5.6 million in July financing and launched a pilot with Ottobock Care.

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation pl

Lifeward Ltd. (Nasdaq: LFWD) said it entered a securities purchase agreement for strategic financing with institutional investors. The initial July 6 closing provides about $5.6M in senior secured convertible notes and warrants, with up to another $5.6M tied to milestones: 150% ReWalk unit sales growth or shares at/above $13.80 for 10 days.

Lifeward Ltd. (NASDAQ:LFWD) shares rose 5.6% after hours after the company said it raised $5.6M via senior secured convertible notes and warrants, with another $5.6M available upon milestones: a 150% increase in ReWalk unit sales or shares trading at/above $13.80 for 10 straight days. Lifeward links the financing to a strategic framework with Oramed (NASDAQ:ORMP).